BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises

Reuters01-12

BRIEF-Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises

Jan 11 (Reuters) - Beam Therapeutics Inc BEAM.O:

BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION
BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302
BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026
BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026

Source text: ID:nGNX4ct14z

Further company coverage: BEAM.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602687495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602687495","market":"nz","top_or_hot":-1,"title":"BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says It Sets Strategic Priorities For Its Genetic Disease &amp; Hematology Franchises</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Beam Therapeutics Inc <span>BEAM.O</span>:</p><ul><li><p>BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION</p></li><li><p>BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302</p></li><li><p>BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026</p></li><li><p>BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026</p></li></ul><p>Source text: <span>ID:nGNX4ct14z</span></p><p>Further company coverage: <span>BEAM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 06:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says It Sets Strategic Priorities For Its Genetic Disease &amp; Hematology Franchises</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Beam Therapeutics Inc <span>BEAM.O</span>:</p><ul><li><p>BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION</p></li><li><p>BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302</p></li><li><p>BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026</p></li><li><p>BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026</p></li></ul><p>Source text: <span>ID:nGNX4ct14z</span></p><p>Further company coverage: <span>BEAM.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA5VTSFN:1","article_id":"2602687495","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602687495","pubTimestamp":1768169128,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology FranchisesJan 11 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","BK4535":"淡马锡持仓","BK4611":"AI医疗","BK4139":"生物科技","BK4588":"碎股","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓"},"translate_title":"BRIEF-Beam Therapeutics表示，它为其遗传病和血液学特许经营权设定了战略重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9},"content_text":"BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology FranchisesJan 11 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITIONBEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026Source text: ID:nGNX4ct14zFurther company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602687495","isCrawlerRequest":true}